Optogenetic Globus Pallidus Stimulation Improves Motor Deficits in 6-Hydroxydopamine-Lesioned Mouse Model of Parkinson's Disease

Int J Mol Sci. 2023 Apr 27;24(9):7935. doi: 10.3390/ijms24097935.

Abstract

Excessive inhibition of the external globus pallidus (GPe) by striatal GABAergic neurons is considered a central mechanism contributing to motor symptoms of Parkinson's disease (PD). While electrophysiological findings support this view, behavioral studies assessing the beneficial effects of global GPe activations are scarce and the reported results are controversial. We used an optogenetic approach and the standard unilateral 6-hydroxydopamine nigrostriatal dopamine (DA) lesion model of PD to explore the effects of GPe photostimulation on motor deficits in mice. Global optogenetic GPe inhibition was used in normal mice to verify whether it reproduced the typical motor impairment induced by DA lesions. GPe activation improved ipsilateral circling, contralateral forelimb akinesia, locomotor hypoactivity, and bradykinesia in 6-OHDA-lesioned mice at ineffective photostimulation parameters (532 nm, 5 Hz, 3 mW) in normal mice. GPe photoinhibition (450 nm, 12 mW) had no effect on locomotor activity and forelimb use in normal mice. Bilateral photoinhibition (450 nm, 6 mW/side) reduced directed exploration and improved working memory performances indicating that recruitment of GPe in physiological conditions may depend on the behavioral task involved. Collectively, these findings shed new light on the functional role of GPe and suggest that it is a promising target for neuromodulatory restoration of motor deficits in PD.

Keywords: Parkinson’s disease; external globus pallidus; mice; motor behavior; optogenetic.

MeSH terms

  • Animals
  • Corpus Striatum
  • Dopamine / physiology
  • Globus Pallidus / pathology
  • Hypokinesia / chemically induced
  • Hypokinesia / pathology
  • Hypokinesia / therapy
  • Mice
  • Optogenetics
  • Oxidopamine
  • Parkinson Disease* / etiology
  • Parkinson Disease* / pathology
  • Parkinson Disease* / therapy

Substances

  • Oxidopamine
  • Dopamine